mepolizumab
Selected indexed studies
- Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. (N Engl J Med, 2017) [PMID:28893134]
- Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. (N Engl J Med, 2017) [PMID:28514601]
- Mepolizumab treatment in patients with severe eosinophilic asthma. (N Engl J Med, 2014) [PMID:25199059]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Dupilumab Versus Mepolizumab for Chronic Rhinosinusitis With Nasal Polyposis: An Indirect Treatment Comparison. (2024) pubmed
- Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. (2023) pubmed
- Mepolizumab treatment in patients with severe eosinophilic asthma. (2014) pubmed
- Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotype. (2025) pubmed
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. (2012) pubmed
- Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. (2017) pubmed
- Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. (2017) pubmed
- Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. (2021) pubmed
- Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO. (2021) pubmed
- Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. (2020) pubmed